RE
BDTX icon

RBC Europe’s Black Diamond Therapeutics BDTX Stock Holding History

RBC Europe’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-135
Closed -$1.14K – 682
2021
Q3 		$1.14K Hold
135
– – ﹤0.01% 1173
2021
Q2 		$1.65K Hold
135
– – ﹤0.01% 1144
2021
Q1 		$3.27K Buy
+135
New +$3.64K ﹤0.01% 1030

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBC Europe's BDTX Position: Q4 2021 in Review

RBC Europe sold out of Black Diamond Therapeutics (BDTX) in Q4 2021, closing a stake of 135 shares — an estimated $1.14K sold.

RBC Europe first reported a position in BDTX in Q1 2021 and held it in 3 quarters. The position peaked at $3.27K in Q1 2021. 95 funds tracked by Wall St. Rank hold BDTX as of Q4 2021.

  • RBC Europe reported no remaining Black Diamond Therapeutics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 135 Black Diamond Therapeutics shares in Q4 2021, an estimated $1.14K.
  • RBC Europe first reported a position in Black Diamond Therapeutics in Q1 2021 and held it in 3 quarters.
  • RBC Europe's Black Diamond Therapeutics position peaked at $3.27K in Q1 2021.
  • 95 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.